Triphase, Celgene deal

In 2014, the companies added a Phase I program to evaluate marizomib plus Avastin bevacizumab

Read the full 153 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE